Myomo

Myomo Announces Pricing of $6.5 Million Upsized Public Offering

Antonette Ho2023-01-17T00:34:18-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses. The closing of the offering is expected to occur on or...

Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial

Ziad2022-11-25T13:59:44-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced receipt of a $120,000 order for MyoPro® units from Cleveland’s Louis Stokes Veterans Administration (“VA”) Medical Center. The primary objective of this trial is to study the efficacy of the MyoPro in motor learning-based therapy for individuals with chronic stroke (>6 months post event) with severe upper limb motor deficits (Fugl-Meyer for Upper Limb score less than 30),...

Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions

Ziad2022-11-25T13:59:45-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces preliminary second quarter revenue and provides an update on its pipeline entering the third quarter. Revenue for the second quarter of 2022 is expected to be $3.4 million to $3.6 million, an increase of 10% to 16% compared with the second quarter of 2021. Read more >>

Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee

Ziad2022-11-25T13:59:57-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint venture (“JV”) in China and the associated impact on first quarter 2022 revenue. As of March 31, 2022, a portion of the technology license fee from the JV Company, Jiangxi Myomo Medical Assistive Appliance Co. Ltd., has been paid. The Company received $1.0 million of the total $2.7 million license fee...

Myomo Strengthens Intellectual Property Portfolio With Receipt of Key Patent in Japan

Ziad2022-11-25T13:59:58-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the granting of patent number 6998478 titled “Powered Orthotic Device and Method of Using Same” by the Japanese Patent Office. This new Japanese patent is part of a family of patents Myomo has been issued for its MyoPro device in the United States, Europe, China and Japan. This family of patents covers a powered orthotic device that supports movement...

Independent Research with Myomo’s MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Chronic Moderate-to-Severe Arm Weakness

Ziad2022-11-25T13:59:58-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that new research measuring the benefits of the Company’s MyoPro myoelectric orthosis found “statistically significant improvements” in a number of motor function measurements. The research study, titled “Myoelectric Arm Orthosis in Motor Learning-Based Therapy for Chronic Deficits After Stroke and Traumatic Brain Injury,” was funded by the U.S. Army Medical Research Acquisition Activity, and supported by the Office of...

Myomo Announces MyoPro® 2+ – Company Continues to Innovate with Digital Technologies

Ziad2022-11-25T13:59:58-05:00Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the availability of MyoPro 2+, an enhanced version of its popular MyoPro powered brace. Deliveries to patients will begin this month. Building on the MyoPro 2, MyoPro 2+ offers lighter weight, easier donning, greater comfort, and improved grasp functionality. Software and firmware enhancements include more powerful and simplified configuration options for clinicians and users as well as customizable...

Myomo, Inc. Announces Granting of Patents in China and Hong Kong

Ziad2022-11-25T14:00:12-05:00 Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the granting of patents in China and Hong Kong covering the Company’s most advanced products. The patents are titled “Powered Orthotic Device and Method of Using Same,” which cover a powered orthotic device that supports movement of a user’s arm about the elbow and a user’s fingers and thumb to support grasping. These newly issued patents are in...

Myomo’s Wearable Completes First Phase of Brain-Computer Interface Trial

Ziad2022-11-25T14:00:12-05:00 Massachusetts medical robotics provider Myomo has developed MyoPro wearable to offer enhanced functionality to patients with neurological disorders and upper-limb paralysis. It has recently announced that Thomas Jefferson University has conducted the first phase of clinical trials leveraging sensors embedded in the brain to control a MyoPro-boosted brace worn by a stroke patient. Read more >>

Myomo Receives Accreditation from HQAA

Ziad2022-11-25T14:00:29-05:00 Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that the Healthcare Quality Association on Accreditation (HQAA) has certified Myomo meets the accreditation requirements under the Social Security Act and federal regulations. Read more >>